XKRX
950220
Market cap17mUSD
Jun 12, Last price
1,228.00KRW
Name
Neoimmunetech Inc
Chart & Performance
P/E
—
P/S
103.54
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-24.74%
Rev. gr., 5y
%
Revenues
170k
Net income
-41m
L-99.92%
CFO
-42m
L-99.92%
Profile
NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 170 | |||||
Cost of revenue | 21,462 | 29,548,150 | 36,985,699 | |||
Unusual Expense (Income) | ||||||
NOPBT | (21,292) | (29,548,150) | (36,985,699) | |||
NOPBT Margin | ||||||
Operating Taxes | 13 | 101,299 | 116,414 | |||
Tax Rate | ||||||
NOPAT | (21,305) | (29,649,449) | (37,102,113) | |||
Net income | (40,883) -99.92% | (53,404,510) -11.59% | (60,405,625) 15.10% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 41,261 | 402,555 | ||||
BB yield | -0.02% | -0.51% | ||||
| Debt | ||||||
Debt current | 8,085 | 1,352,622 | 1,279,295 | |||
Long-term debt | 6,522 | 6,463,214 | 8,423,599 | |||
Deferred revenue | ||||||
Other long-term liabilities | 293 | 213,934 | 206,766 | |||
Net debt | (32,423) | (63,450,439) | (107,543,230) | |||
| Cash flow | ||||||
Cash from operating activities | (42,098) | (49,760,750) | (42,404,803) | |||
CAPEX | (1,670) | (791) | (2,476,539) | |||
Cash from investing activities | (12,470) | 2,087 | (3,150,258) | |||
Cash from financing activities | 12,089 | (1,136) | (633,323) | |||
FCF | 7,720,461 | (28,001,021) | (37,443,341) | |||
| Balance | ||||||
Cash | 34,835 | 69,072,408 | 117,075,102 | |||
Long term investments | 12,195 | 2,193,867 | 171,022 | |||
Excess cash | 47,022 | 71,266,275 | 117,246,124 | |||
Stockholders' equity | (325,182) | (246,514,445) | (170,955,181) | |||
Invested Capital | 377,908 | 325,492,669 | 295,610,160 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 19,653 | 98,849 | 19,728 | |||
Price | 1,125.00 -44.44% | 2,025.00 -49.31% | 3,995.00 -61.40% | |||
Market cap | 22,110,003 -88.95% | 200,170,217 153.99% | 78,811,390 -59.98% | |||
EV | 22,077,580 | 136,719,778 | (28,731,840) | |||
EBITDA | (17,334) | (26,338,569) | (34,183,617) | |||
EV/EBITDA | 0.84 | |||||
Interest | 726 | 225,280 | 261,390 | |||
Interest/NOPBT | ||||||